Akari Therapeutics
AKTX
16 hedge funds and large institutions have $1.71M invested in Akari Therapeutics in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
45% more funds holding
Funds holding: 11 → 16 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
7% less capital invested
Capital invested by funds: $1.84M → $1.71M (-$126K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cerity Partners
New York
|
+$58.4K |
| 2 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
+$39.2K |
| 3 |
Renaissance Technologies
New York
|
+$6.36K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.48K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$3.18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$99.3K |
| 2 |
Millennium Management
New York
|
-$22.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $1.26M | -$99.3K | -687 | -7% |
|
|
OFW
2
Omnia Family Wealth
Aventura,
Florida
| $133K | – | – | – |
|
|
NMC
3
NEA Management Company
Timonium,
Maryland
| $76.9K | – | – | – |
|
|
4
Cerity Partners
New York
| $54.9K | +$58.4K | +404 | New |
|
|
5
Renaissance Technologies
New York
| $54K | +$6.36K | +44 | +12% |
|
|
CAM
6
Cresset Asset Management
Chicago,
Illinois
| $36.8K | +$39.2K | +271 | New |
|
7
LPL Financial
San Diego,
California
| $22.9K | – | – | – |
|
|
8
Millennium Management
New York
| $22.8K | -$22.8K | -158 | -48% |
|
|
HP
9
Hikari Power
Tokyo,
Japan
| $22K | – | – | – |
|
|
BMCM
10
Bryn Mawr Capital Management
Philadelphia,
Pennsylvania
| $17K | – | – | – |
|
11
Geode Capital Management
Boston,
Massachusetts
| $5.14K | – | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| $4.16K | +$4.48K | +31 | New |
|
|
VF
13
Virtu Financial
New York
| $3K | +$3.04K | +21 | New |
|
|
TSS
14
Two Sigma Securities
New York
| $2.99K | +$3.18K | +22 | New |
|
15
Bank of America
Charlotte,
North Carolina
| $510 | – | – | – |
|
|
TC
16
Truvestments Capital
Sarasota,
Florida
| $171 | – | – | – |
|
AKTX Hedge Fund Activity: Q2 2023 in Review
16 of the 6,371 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q2 2023, worth a combined $1.71M — down 6.9% from $1.84M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new AKTX positions and 0 closed out — a net gain of 5 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Cerity Partners, opening a new position worth an estimated $58.4K. The largest seller was Sabby Management, cutting an estimated $99.3K.
- 16 institutional investors held Akari Therapeutics (AKTX) as of Q2 2023, up from 11 in Q1 2023.
- Funds reported $1.71M of Akari Therapeutics stock for Q2 2023, down 6.9% quarter-over-quarter.
- 5 funds opened new Akari Therapeutics positions in Q2 2023 and 0 closed out, a net change of +5 holders.
- The largest Akari Therapeutics buyer in Q2 2023 was Cerity Partners, an estimated $58.4K added.
- The largest Akari Therapeutics seller in Q2 2023 was Sabby Management, an estimated $99.3K sold.
Based on aggregated 13F filings for Q2 2023.